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Assessment, University of Glasgow, Glasgow, UKA B S T R A C TBackground: Previous economic evaluations of cinacalcet in patients
with secondary hyperparathyroidism (sHPT) relied on the combina-
tion of surrogate end points in clinical trials and epidemiologic
studies. Objectives: The objective was to conduct an economic eval-
uation of cinacalcet on the basis of the EValuation Of Cinacalcet HCl
Therapy to Lower CardioVascular Events (EVOLVE) trial from a US
payer perspective. Methods: We developed a semi-Markov model to
assess the cost-effectiveness of cinacalcet in addition to conventional
therapy, compared with conventional therapy alone, in patients with
moderate-to-severe sHPT receiving hemodialysis. We used treatment
effect estimates from the unadjusted intent-to-treat (ITT) analysis
and prespeciﬁed covariate-adjusted ITT analysis as our main analy-
ses. We assessed model sensitivity to variations in individual inputs
and overall decision uncertainty through probabilistic sensitivity
analyses. Results: The incremental cost-effectiveness ratio (ICER) for
cinacalcet was $61,705 per life-year and $79,562 per quality-adjustedee front matter & 2015 Published by Elsevier Inc.
(ISPOR).
.1016/j.jval.2015.08.007
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ndence to: Vasily Belozeroff, Amgen Health Econolife-year (QALY) gained using the covariate-adjusted ITT analysis.
Probabilistic sensitivity analysis suggested a 73.2% chance of the ICER
being below a willingness-to-pay threshold of $100,000. Treatment
effects from unadjusted ITT analysis yielded an ICER of $115,876 per
QALY. The model was most sensitive to the treatment effect on
mortality. Conclusions: In the unadjusted ITT analysis, cinacalcet
does not represent a cost- effective use of health care resources when
applying a willingness-to-pay threshold of $100,000 per QALY. When
using the covariate-adjusted ITT treatment effect, which represents
the least biased estimate, however, cinacalcet is a cost-effective
therapy for patients with moderate-to-severe sHPT on hemodialysis.
Keywords: cinacalcet, cost-effectiveness, dialysis, hyperpara-
thyroidism.
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Patients suffering from end-stage renal disease (ESRD) frequently
develop secondary hyperparathyroidism (sHPT), a progressive
disease associated with persistent elevations in serum concen-
trations of biochemical markers of mineral metabolism including
parathyroid hormone (PTH), calcium, and phosphate [1]. The goal
of sHPT treatment is to manage the biochemical markers of
mineral metabolism, which are linked to cardiovascular (CV)
events and fractures by extensive epidemiologic evidence [2–5].
These complications are burdensome to patients and worsen the
already heavy ﬁnancial costs of dialysis [6–8]. Various forms of
vitamin D sterols and phosphate binders along with dietary
phosphorus restriction have traditionally been used in clinical
practice to manage sHPT. For patients with more severe disease
and who fail to respond adequately to medical therapy, total orpartial surgical removal of parathyroid glands, that is, parathyr-
oidectomy, is considered a viable option according to current
practice guidelines [9].
Over the last decade, cinacalcet, a calcimimetic agent, has
been added to conventional therapies for this indication because
it effectively suppresses PTH [10]. Cost-effectiveness analyses of
cinacalcet have been previously published in the United States
[11,12], Europe [13–15], and Japan [16]. Boer et al. [11] reported that
cinacalcet could be considered cost-effective in the United States
if the willingness-to-pay threshold was $100,000 per quality-
adjusted life-year (QALY), while Ray et al. [12] found that
cinacalcet could be cost-effective if initiated in patients with less
severe, compared to more severe, sHPT. The European analyses
[13,14] also found acceptable cost-effectiveness results for cina-
calcet in ﬁve European countries. In contrast, the study by
Garside et al. [15] concluded that cinacalcet was unlikely to beon behalf of International Society for Pharmacoeconomics and
rom Amgen in relation to preparing the analysis. P. S. Parfrey and
eceived consulting fees from Amgen. C. N. Graham has received
preparing the analysis reported in this article. B. Dehmel and V.
mics, One Amgen Center Drive, Thousand Oaks, CA 91320.
Table 1 – Demographic and clinical characteristics
by treatment group*.
Characteristic Cinacalcet
(N ¼ 1948)
Placebo
(N ¼ 1935)
Age (y), median (10%–90%) 55.0 (35.0–74.0) 54.0 (35.0–73.0)
Sex: female (%) 41.5 39.7
Race or ethnic group (%)
White 57.7 57.7
Black 21.0 22.1
Other 21.3 20.2
Body mass index (kg/m2),
median (10%–90%)
26.3 (20.4–36.4) 26.4 (20.6–36.7)
Months on dialysis,
median (10%–90%)
45.4 (8.5–142.0) 45.1 (9.9–149.6)
Medical history (%)
Diabetes 33.6 33.5
Cardiovascular disease,
including
hypertension
95.4 94.6
Heart failure 23.1 23.6
Peripheral vascular
disease
16.1 16.6
Myocardial infarction 12.3 12.6
Stroke 8.3 10.0
* These baseline characteristics, along with region, tobacco use,
type of vascular access, blood pressure, high-density lipoprotein,
calcium-phosphate product (CAxP), and albumin, were included
in the covariate-adjusted analysis. There were no signiﬁcant
differences between the two groups except for mean diastolic
blood pressure (P ¼ 0.02) and transient ischemic attack (Po 0.05).
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considering Japanese settings [16] concluded that cinacalcet was
likely to be cost-effective only for those patients who cannot
undergo surgical parathyroidectomy. The seemingly inconsistent
conclusions of these reports reﬂect heterogeneity of the modeling
assumptions and costs across regions.
One important aspect that is common across previously
published cost-effectiveness analyses is the reliance on trials
using surrogate outcomes, that is, laboratory markers of sHPT
such as PTH, calcium, and phosphate, to ascertain efﬁcacy
estimates. Then, lifetime projections for survival and costs are
derived from risks attributable to these laboratory parameters
based on large epidemiologic studies (e.g., as shown in Block et al.
[4]). Although common in modeling studies, this approach relies
on the assumption that surrogate markers do indeed affect hard
outcomes. This important gap can be addressed only in a
randomized trial designed to assess effects of a therapy on hard
outcomes.
The EValuation Of Cinacalcet HCl Therapy to Lower Cardio-
Vascular Events (EVOLVE) randomized controlled trial [17] exam-
ined the effects of cinacalcet on hard outcomes. Although the
EVOLVE trial failed to show a statistically signiﬁcant beneﬁt of the
active treatment group compared with placebo using an unad-
justed intent-to-treat (ITT) analysis, an ITT analysis adjusted for
baseline characteristics, lag-censoring, and other analyses
showed nominally signiﬁcant reductions in the risk of death or
major CV events. Completion of the EVOLVE trial made it possible
to address the important gaps in the economic evaluations of
cinacalcet highlighted above, particularly by providing a robust
data set in which the estimates of effects of cinacalcet on hard
outcomes were directly evaluated within the scope of the trial.
The objective of this article was to provide an economic evalua-
tion of cinacalcet in the context of the US health care system
using data from the EVOLVE trial.Methods
Clinical Trial
EVOLVE was a global, double-blind, randomized, placebo-controlled
trial evaluating the effects of cinacalcet versus placebo, both in
addition to conventional therapy, that is, vitamin D sterols and
phosphate binders, on death or major CV events in patients with
moderate-to-severe sHPT receiving hemodialysis [17]. Major
baseline covariates included demographic and clinical character-
istics, comorbidities, and history of CV events and fractures
(Table 1). The primary composite end point in the EVOLVE study
was death or ﬁrst nonfatal myocardial infarction, hospitalization
for unstable angina, heart failure, or a peripheral vascular event.
Secondary end points included CV death, stroke, clinical fracture
(there was no radiologic screening for fractures during the trial),
and parathyroidectomy. Laboratory-based outcomes and health-
related quality of life were also assessed. The primary unadjusted
ITT analysis showed that patients randomized to cinacalcet
experienced numerically fewer composite events, but the risk
reduction was not statistically signiﬁcant (relative hazard 0.93;
95% conﬁdence interval [95% CI] 0.85–1.02; P ¼ 0.11).
The analysis of baseline characteristics revealed that patients
randomized to cinacalcet were approximately 1 year older than
those randomized to placebo. The age imbalance was manifested
at the extremes of the distribution, with fewer patients random-
ized to cinacalcet than to placebo in the younger than 50 years
age group in which the risk of clinical events is lower. In addition,
more patients randomized to cinacalcet than to placebo were in
the older than 70 years age group in which the risk of clinical
events is particularly high. It is likely that the observed ageimbalance occurred by chance because the likelihood of imbal-
ance is dictated by the SD for age and the sample size. The
probability of an age difference of more than 0.8 years occurring
in the EVOLVE trial was 0.08, as the SD for age was 14 years,
which is larger than in other CV trials. In comparison, owing to
more restrictive inclusion criteria and older patients enrolled, the
SD for age was lower in the Study of Heart and Renal Protection
(SHARP) trial [18]—12 years—and the Trial to Reduce Cardiovas-
cular Events with Aranesp Therapy (TREAT) [19] trial—10 years,
with a probability of observing an age difference of more than 0.8
years between groups of 0.04 and 0.01, respectively (P.S. Parfrey
PS, G.A. Block, R. Correa-Rotter R, et al., unpublished data, 2015).
The prespeciﬁed analysis adjusting for baseline characteristics
including age showed a relative hazard of 0.88 (95% CI 0.79–0.97; P
¼ 0.008) for the primary composite end point, or a nominally
statistically signiﬁcant 12% risk reduction with cinacalcet than
with placebo.
The study drug discontinuation rates were high: 67% and 71%
in the groups randomized to cinacalcet and placebo, respectively.
Off-protocol (commercial) cinacalcet was commonly prescribed
after study drug discontinuation—11.4% and 19.8% in the groups
randomized to cinacalcet and placebo, respectively. This cross-
over effect, that is, discontinuation of study drug in the cinacalcet
group and use of commercial cinacalcet in the placebo group, is
expected to reduce the observed effect size. To minimize this
cross-over effect, a prespeciﬁed lag-censoring analysis was con-
ducted. This lag-censoring analysis used the full ITT cohort but
censored the follow-up time at 6 months postdiscontinuation [17]
and was intended to take account of drug effects that may persist
after discontinuation. The results showed a consistent treatment
effect for cinacalcet, with a relative hazard risk of 0.85 for the
primary composite end point (95% CI 0.76–0.95; P ¼ 0.003), or a
15% nominally statistically signiﬁcant reduction in risk. The
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statistical methods fully described elsewhere [20]. The primary
ITT analysis, as well as the prespeciﬁed covariate-adjusted and
lag-censored analysis, is described in the EVOLVE primary manu-
script [17].
We analyzed the cost-effectiveness of cinacalcet using a range
of clinical effect estimates—unadjusted and covariate-adjusted
ITT, and lag-censoring. Because controlling for baseline covariate
imbalances will improve the internal validity of the estimate, the
covariate-adjusted ITT analysis is the least biased and the most
relevant for the payer perspective. The unadjusted ITT analysis is
likely biased because of the age imbalance, and the lag-censoring
analysis, while also interesting because it reﬂects the effects of
the medication when patients actually take it and is less relevant
for a “real-world” situation in which adherence is imperfect.
Therefore, we focused primarily on the adjusted and unadjusted
ITT analyses, and used lag-censoring treatment effects as a part
of scenario analyses.Model Overview
We developed a semi-Markov model to assess the cost-
effectiveness of cinacalcet plus conventional therapy (referred
to as the cinacalcet group) compared with conventional therapy
(referred to as the conventional therapy group) in patients with
sHPT receiving hemodialysis. Consistent with the EVOLVE trial
inclusion criteria, the model population was deﬁned as adults
with ESRD who had been treated with maintenance hemodialysis
three times a week for 3 months or more who had a PTH level of
300 pg/ml or more, serum calcium level of 8.4 mg/dl or more, and
calcium-phosphorus products level of 45 mg2/dL2 or more. Con-
ventional therapy was administered at the treating physician’s
discretion and typically, but not always, included vitamin D
sterols and phosphate binders.
A patient cohort enters the model in the event-free health
state (Fig. 1). The transitions from the event-free state are to the
following states: Nonfatal CV event: In this health state, patients
are alive and are experiencing myocardial infarction, hospitalized
unstable angina, heart failure, or peripheral vascular event; and
fracture: In this health state, patients are alive and are experi-
encing a clinical fracture.
The postevent states (modeled as a series of three short-term
tunnel states and one long-term postevent state) deﬁned over theFig. 1 – Model structure. Notes. PTx costs and utility decrements
costs, disutility, and probability of PTx to the number of patients
only (as in the EVOLVE trial) and is modeled outside of the Mark
which PTx was not treated as a censoring event (e.g., CV and b
utility decrements associated with the PTx surgery are applied
cardiovascular; EVOLVE, EValuation Of Cinacalcet HCl Therapy t
QALY, quality-adjusted life-year. *PTx was included in the mode
nonfatal CV event, and nonfatal fracture event health states. ‡Pa
health state.course of 1 year after an event allow the model to account for any
lingering effects on health-related quality of life and for the
potential increased costs after the events. After the postevent
state, the event rates and costs return to those associated with
the event-free health state. Patients in the postevent states can
transition back to CV events, parathyroidectomy, or remain in the
postevent health states. Patients may transition to the death
health state from any other health state in the model.
To be consistent with the design of the EVOLVE trial, para-
thyroidectomies were modeled as outcomes; that is, at the time
of parathyroidectomy, the costs of surgery including follow-up
costs and disutilities were applied, and patients continued to be
at risk for other outcomes.
The lack of memory in the semi-Markov model could lead
to an underestimation of the impact of subsequent events
of different types on costs and utilities in our analysis. For
example, a fracture after a CV event would have a greater effect
on quality of life than one of the two outcomes alone. We
addressed this through the use of state prevalence estimates of
the expected number of patients in the postevent health states.
Costs and QALYs were adjusted proportionality to the number of
patients in the postevent states expected to have both outcomes
(fracture and CV event) simultaneously. To avoid double count-
ing, we did not apply the above calculations for transitions
between events of the same type, and assumed the cost and
disutilities of the acute event taking precedence over those of the
chronic event.
The model assumed a lifetime horizon and used a 3-month
cycle. We discounted all costs and outcomes at 3% per year. We
developed the model using Microsoft Excel for Windows.Model Inputs
Model inputs include clinical, economic, and health-related
quality-of-life data; these were estimated from patient-level data
analysis of the EVOLVE trial, and collected from the published
literature and standard costing sources.
The rates of clinical events were estimated from the EVOLVE
placebo group for each event of interest, that is, death, nonfatal
CV event, nonfatal fracture, and parathyroidectomy (Table 2). For
each event type, the person time was calculated from the
randomization to the ﬁrst occurrence of the event and censored
at death or end of follow-up in the study (for the ITT analysis) or 6are calculated outside the Markov by applying the expected
alive. In the base-case analysis, PTx is treated as an outcome
ov. This follows the statistical analysis of the EVOLVE trial in
one fracture events were counted post-PTx). The costs and
to the per-cycle cost and QALY calculations. CV,
o Lower CardioVascular Events; PTx, parathyroidectomy;
l as an outcome that could be experienced in the event-free,
tients may progress to the death health state from any other
Table 2 – Event rates, utilities, and cost inputs.
Annual event rates in conventional therapy, ﬁrst (subsequent) event Source
Health state ITT Lag-censoring
All-cause death 0.10 (NA) 0.10 (NA) [17]
Cardiovascular event* 0.08 (0.43) 0.10 (0.57) [17]
Stroke 0.01 (0.01) 0.01 (0.01) [17]
Bone fracture 0.04 (0.11) 0.04 (0.11) [17]
Parathyroidectomy 0.05 (NA) 0.05 (NA) [17]
Health state Utilities Source
Event-free 0.75 [43]
Cinacalcet 0.02 [43]
Acute effect† Chronic effect†
Cardiovascular event* 0.19 0.14 [43]
Stroke 0.20 0.11 [43]
Bone fracture 0.31 0.12 [43]
Parathyroidectomy 0.06 0.00 [43]
Cost center Costs ($) Source
Cardiovascular event* 22,063 [7]
Stroke 21,618 [7]
Bone fracture 15,664 [7]
Parathyroidectomy 19,511 [40,41]
Cinacalcet 0.560/mg [42]
Calcium acetate 0.001/mg [42]
Sevelamer 0.004/mg [42]
Lanthanum carbonate 0.008/mg [42]
Calcitriol oral (IV) 3.060 (5.000)/μg [42]
Doxercalciferol oral (IV) 8.620 (3.130)/μg [42]
Paricalcitol oral (IV) $10.270 ($3.030)/μg [42]
EQ-5D, EuroQol ﬁve-dimensional questionnaire; EVOLVE, EValuation Of Cinacalcet HCl Therapy to Lower CardioVascular Events; ITT, intent to
treat; IV, intravenous; NA, not applicable/available.
* Myocardial infarction, hospitalization for unstable angina, heart failure, or peripheral vascular event. Costs for cardiovascular events and
fractures were calculated as a weighted average using the estimates from Lee et al [7]. for individual events and weights from the EVOLVE
distribution of events in the ITT cohort. Costs inﬂated to February 2013 US dollars, using the medical component of the Consumer Price Index
[23].
† Acute and chronic effects, i.e., reductions in utility, were estimated form the EQ-5D data in the EVOLVE trial using generalized estimation
equations for the months 0 to 3, and for the months 4 to 12 after the event, [43].
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 7 9 – 1 0 8 71082months after discontinuation of the study drug (lag-censored
analysis). The rate of subsequent events of each kind was
estimated similarly in subjects who had an initial event of that
kind. Naturalistic rates of the events in the US dialysis population
were used as reported in the literature [11].
We assessed utilities for the health states using the EuroQol
ﬁve-dimensional questionnaire (EQ-5D) data collected in the
EVOLVE trial [43]. Patients were administered the EQ-5D instru-
ment at baseline, and during the study visits at weeks 20, 52, 100,
148, 196, and 244. The EQ-5D data were also collected after a
study-deﬁned clinical event. The EQ-5D scores were converted to
utilities on the basis of time trade-off responses from a repre-
sentative sample of 2997 noninstitutionalized individuals in the
United Kingdom [21]. We conducted a regression analysis to
explain the EQ-5D utility using events as explanatory variables
along with baseline utility score and an indicator variable for
treatment group. Two different effects of events were considered
(short-term and long-term). The short-term effect represents the
disutility of an event within the ﬁrst 3 months after the onset of
the event, whereas long-term effects represent the disutility in all
subsequent months postevent. The EQ-5D inputs for the modelare summarized in Table 2 for the direct effects of cinacalcet and
clinical events, and the full set of results from the regression
analysis is presented in Appendix Table A1 in Supplemental
Materials found at: http://dx.doi.org/10.1016/j.jval.2015.08.007.
The model assumed half-recovery from the chronic effect beyond
1 year postevent.
We estimated health state costs for fatal and acute nonfatal CV
events and fractures as the weighted average costs of the individ-
ual events that make up each category applied to published data
from a claims analysis of costs for nonfatal CV events, fractures,
and parathyroidectomies in the population with ESRD [7] (Table 2).
Fatal CV event costs were based on the article by O’Sullivan et al.
[22]. Acute costs described above are associated with a hospital-
ization directly after the event. Postevent costs capture costs
associated with outpatient and nursing facility costs after hospital
discharge. We modeled these costs for 9 months after the acute
event. Costs were inﬂated to February 2013 US dollars, using the
medical component of the Consumer Price Index [23].
Effect sizes were estimated from the EVOLVE data using
proportional hazards models (Table 3). Because there was no
clear effect modiﬁcation by subsequent events in the repeated
Table 3 – Treatment effect estimates.
End point Effect size as measured by hazard ratio (95% CI), cinacalcet vs. placebo
ITT unadjusted ITT covariate-adjusted* Lag-censoring*
All-cause death 0.94 (0.85–1.04) 0.87 (0.78–0.97) 0.80 (0.69–0.91)
CV event† 0.86 (0.76–0.98) 0.85 (0.74–0.97) 0.78 (0.67–0.91)
Stroke 1.07 (0.82–1.40) 1.07 (0.79–1.45) 0.95 (0.67–1.36)
Bone fracture 0.89 (0.75–1.07) 0.86 (0.72–1.04) 0.73 (0.59–0.92)
Parathyroidectomy 0.44 (0.36–0.54) 0.42 (0.34–0.51) 0.25 (0.19–0.33)
CI, conﬁdence interval; CV, cardiovascular; HDL, high-density lipoprotein; ITT, intent to treat.
* Adjusted for baseline covariates: age, sex, race, region, body mass index, time on dialysis, history of CV disease, blood pressure, diabetes,
retinopathy, tobacco use, type of vascular access, HDL, calcium-phosphate product (CaxP), and albumin.
† Myocardial infarction, hospitalization for unstable angina, heart failure, or peripheral vascular event.
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events as well as to subsequent events.
We used parametric survival models to project posttrial
survival and rates of clinical events. The model ﬁts were assessed
using Akaike information criterion and tested qualitatively for
the external validity on the basis of the expected survival over
the lifetime. We used published literature estimates for mortality
rates in general dialysis population between 23.0 per 100 patient-
years [24] and 26.6 per 100 patient-years reported in reference
[25]. Based on the Akaike information criterion statistics and on
the projected survival beyond the trial, the Weibull distribution
was best ﬁt for the lifetime projections. Model ﬁt coefﬁcients for
the survival analysis on the mortality input are summarized in
Appendix Table A2 in Supplemental Materials found at: http://dx.
doi.org/10.1016/j.jval.2015.08.007. A scenario analysis was con-
ducted to address the issue of differences in event rates.
Comedications and Treatment Discontinuation
The use and doses of comedications for sHPT are summarized in
Appendix Table A3 in Supplemental Materials found at http://dx.
doi.org/10.1016/j.jval.2015.08.007. Comedications were tracked
prospectively—the doses of vitamin D were recorded directly
from the trial. Phosphate binders were tracked in the trial as a
type of binder; we estimated the dose using the maximum
recommended doses for product labels. Not all patients received
vitamin D sterols; therefore, costs are calculated only for those
receiving vitamin D sterols. In the ﬁrst year, 74.2% of the patients
randomized to cinacalcet and 77.3% of the patients randomized
to placebo group received vitamin D sterols. Similarly, by averag-
ing subsequent years of treatment (years 2þ), 73.3% and 81.6% of
the patients, respectively, received vitamin D sterols.
We modeled treatment discontinuation from cinacalcet by
applying the annual probability of discontinuation as seen in the
EVOLVE trial, that is, 27.3%. Because 19.8% of the subjects
randomized to the placebo group started commercial cinacalcet
at some point during the trial, we tested the model sensitivity to
the inclusion of these costs in scenario analyses.
Perspectives and Analyses
The model assumes the perspective of a third-party payer (e.g., a
managed care organization in the United States). We considered
only direct medical costs, that is, costs related to cinacalcet and
other sHPT medication use, and costs due to CV events, fractures,
and parathyroidectomies. Outcomes were valued in terms of
incremental life-years and QALYs. The cost-effectiveness was
assessed in terms of incremental cost-effectiveness ratio (ICER)
per life-year gained and per QALY gained.
Using the event rates estimated from the EVOLVE ITT analysis
and assuming that treatment effects observed in the trial wereattenuated beyond the trial period proportionately to treatment
discontinuation, we assessed the cost-effectiveness of cinacalcet
using clinical effect estimates from the covariate-adjusted ITT
analysis and unadjusted ITT analysis.
We further conducted a range of scenario analyses using
effect estimates from the covariate-adjusted ITT analysis: 1) used
treatment effect estimated from the lag-censoring analysis; 2)
assumed full treatment effects for the lifetime; 3) assumed
treatment effect for the duration of the trial only; 4) used
naturalistic event rates from the US dialysis population (see
Appendix Table A4 in Supplemental Materials found at: http://
dx.doi.org/10.1016/j.jval.2015.08.007); 5) excluded costs of com-
mercial cinacalcet from the placebo group; 6) assumed beneﬁcial
effect of parathyroidectomy on the clinical events of 10% and [6]
20%; 7) included stroke in the deﬁnition of the CV event state; and
8) included the cost of commercial cinacalcet in patients who
reinitiate cinacalcet in the active arm after discontinuation (there
were a total of 222 subjects who reinitiated commercial cinacalcet
in the cinacalcet arm, or a reinitiation rate of 3.7%, and we
modeled this scenario by reducing the discontinuation rate of
cinacalcet of 27.3% by that amount, i.e., to be 23.6%), and 10)
included dialysis costs to represent limited societal perspective.
In addition to the scenario analyses, we conducted a one-way
sensitivity analysis in which the model input parameters were
varied individually using reasonable lower and upper bounds of
each parameter, that is, 95% conﬁdence limits for the estimated
parameters, and 20% variation on the list price of cinacalcet.
Last, we performed a second-order Monte-Carlo probabilistic
sensitivity analysis to evaluate the impact of simultaneous
variation in clinical outcomes and resource utilization parame-
ters (for the sampling distributions, see Appendix Table A5 in
Supplemental materials found at http://dx.doi.org/10.1016/j.jval.
2015.08.007) on the model results and presented the results as
cost- effectiveness acceptability curves for each of the scenario
analyses.Results
Table 4 summarizes the results of the analyses over the lifetime
for treatment effect estimates from the covariate-adjusted and
unadjusted ITT analyses. In each treatment effect estimate,
cinacalcet therapy was associated not only with increased life-
years (0.55, 0.25) and QALYs (0.42, 0.23) but also with increased
lifetime costs ($33,809, $27,114). The respective ICERs were
$79,562 and $115,876 per QALY.
Table 5 summarizes results of the additional scenario anal-
yses around covariate-adjusted ITT treatment effect estimates.
The results are presented in the order of increasing (less
favorable) cost-effectiveness. Using the assumptions of the full
treatment effect beyond the duration of the trial decreased the
Table 4 – Results of the model simulation for the adjusted and unadjusted ITT effect estimates.
ITT, covariate-adjusted ITT, unadjusted
Costs and outcomes Cinacalcet Conventional
therapy
Difference Cinacalcet Conventional
therapy
Difference
Cost category ($)
Cinacalcet 51,944 5,068 46,875 50,350 5,068 45,282
Usual care 97,281 103,874 –6,592 93,743 103,874 –10,131
CV-related 57,512 60,253 –2,741 56,104 60,253 –4,149
Fracture-related 10,121 10,401 –280 9,918 10,401 –483
PTx-related 2,838 6,291 –3,453 2,886 6,291 –3,405
Total 219,696 185,887 33,809 213,001 185,887 27,114
Outcome category
LYs gained 8.14 7.59 0.55 7.84 7.59 0.25
QALYs gained 5.47 5.04 0.42 5.28 5.04 0.23
ICER per LY gained 61,705 107,691
ICER per QALY gained 79,562 115,876
Note. Costs and outcomes are discounted at 3% per year; costs inﬂated to February 2013 US dollars, using the medical component of the
Consumer Price Index [23].
CV, cardiovascular; ICER, incremental cost-effectiveness ratio; ITT, intent to treat; LY, life-year; PTx, parathyroidectomy; QALY, quality-
adjusted life-year.
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assumption of limiting cinacalcet effect to the duration of the
trial increased the ICER to $98,220 per QALY. Including stroke,
applying naturalistic event rates to the conventional therapy
group, and assuming a 10% beneﬁcial effect of parathyroidec-
tomy had a small worsening effect on the ICER, moving it up to
approximately $83,000 per QALY. The assumption of the 20%
positive effect of parathyroidectomy and exclusion of the com-
mercial cinacalcet costs in the conventional therapy group had
somewhat more pronounced worsening effect, moving the ICER
to approximately $89,000 per QALY. Including the cost of
commercial cinacalcet in the cinacalcet group did not materially
change the ICER ($79,711 per QALY). The inclusion of dialysis
costs in the analysis substantially increased the ICER to $191,072
per QALY.
With lag-censoring effect estimates, the ICER was $56,686
per QALY.
Results of the one-way sensitivity analyses are summarized in
the form of a tornado diagram in Figure 2, which shows the ﬁve
most sensitive parameters in the model. Overall, model results
were most sensitive to the effect estimates for survival, the cost
of cinacalcet, followed by effects on fracture, cinacalcet-related
utility, and CV death.Table 5 – Results of the model simulation: Scenario anal
Simulation scenario ΔLY
Lifetime treatment effect 0.82
Include commercial cinacalcet cost in the cinacalcet arm 0.55
Include stroke 0.55
Naturalistic event rates 0.46
PTx improves outcomes by 10% 0.50
PTx improves outcomes by 20% 0.46
Exclude commercial cinacalcet cost from the placebo arm 0.55
Study duration treatment effect only 0.40
Include dialysis costs 0.55
Note. Costs inﬂated to February 2013 US dollars, using the medical comp
ICER, incremental cost-effectiveness ratio; LY, life-years; PTx, parathyroiResults of a probabilistic sensitivity analysis indicated that for
most of the simulated scenarios, the ICER was less than $100,000
per QALY in more than 60% of the simulation runs. In the
scenarios in which treatment effect is limited to trial duration
only or in which the unadjusted ITT effect estimates are
assumed, the proportions of simulation runs with ICER less than
$100,000 per QALY are 48% and 39%, respectively. Inclusion of
dialysis costs produces an ICER of less than $100,000 per QALY in
only 2% of the simulation runs. Results of the probabilistic
sensitivity analyses are presented as cost-effectiveness accept-
ability curves (Fig. 3) in which costs per incremental QALYs are
plotted on the X axis and the probability of being cost-effective is
plotted on the Y axis, with the plots arranged in the order of
decreasing probability of cinacalcet being cost-effective.Discussion
We conducted a cost-effectiveness analysis of cinacalcet using
data from the EVOLVE trial, taking the US health care pers-
pective, in which the ICER was sensitive to treatment effect
estimates; that is, using the covariate-adjusted ITT analysis and
unadjusted ITT analysis, the ICER was $79,562 and $115,876 peryses.
ΔQALY ΔCost ($) ICER per LY ICER per QALY ($)
0.59 37,413 45,711 63,147
0.42 33,987 62,030 79,711
0.43 34,655 63,249 81,026
0.38 31,647 68,610 83,169
0.40 33,341 66,190 83,547
0.37 32,827 72,126 88,564
0.43 38,877 70,955 89,916
0.35 34,210 86,170 98,220
0.42 81,194 148,188 191,072
onent of the Consumer Price Index [23].
dectomy; QALY, quality-adjusted life-year.
Fig. 2 – One-way sensitivity analysis. CI, conﬁdence interval;
CV, cardiovascular; HR, hazard ratio; QALY, quality-adjusted
life-year.
Fig. 3 – Cost-effectiveness acceptability curves for scenario
analyses. Probabilistic sensitivity analyses and probability
of being cost-effective at $100,000 per QALY: 1) Lag-censored
effect size (97.7%), 2) lifetime full effect (90.2%), 3) adjusted
ITT effect size (73.2%), 4) PTx improves outcomes by 20%
(59.3%), 5) effects limited to the trial duration (48.4%), 6)
unadjusted ITT effect size (39.0%). Curves not shown for the
following scenarios: Include stroke (72.6%), PTx improves
outcomes by 10% (68.5%), naturalistic rates in the
comparator arm (68.2%), exclude commercial cinacalcet
costs (64.4%), including dialysis costs (2.0%). ITT, intent to
treat; PTx, parathyroidectomy; QALY, quality-adjusted life-
year.
V A L U E I N H E A L T H 1 8 ( 2 0 1 5 ) 1 0 7 9 – 1 0 8 7 1085QALY, respectively. This is consistent with an earlier cost-utility
analysis in the United States that extrapolated data from
observational studies [11] and reported the ICER in the range
of $54,000 to $75,000 per QALY. Our results being slightly higher
are likely explained by the changes in cinacalcet price over time,
and a higher dose of cinacalcet in our analysis than in previous
studies.
The unique strength of our analysis is that it is based on a
randomized controlled trial that directly assessed the effect of
cinacalcet therapy on clinical outcomes. Although the result of
the primary analysis of the EVOLVE trial—an unadjusted ITT
analysis—was not statistically signiﬁcant, treatment effect esti-
mates were inﬂuenced by imbalance in age at randomization and
high rates of discontinuation of study drug in both cinacalcet and
placebo groups. We used effect estimates from unadjusted ITT
analysis and prespeciﬁed lag-censoring and covariate-adjusted
ITT analyses to inform treatment effect inputs for our model.
Using covariate-adjusted ITT analysis allowed adjustment for
potential confounders at randomization and improved internal
validity of the treatment effect estimates. Patients with sHPT on
dialysis range from very young to very old; that is, the SD of age
in this population is large compared with most other large
outcome studies in patients with other CV disease in which the
age range of the population is narrower. Other large randomized
controlled trials have shown changes in effect estimates after
adjustment for unexpected differences in baseline determinants
of risk [26–28]. Although the ITT principle in general should
represent the least biased measure of the treatment effect,
imbalance in age at randomization in the EVOLVE trial makes
the covariate-adjusted ITT analysis less biased than the unad-
justed analysis.
Importantly, we approached this analysis from the estima-
tion, rather than a hypothesis testing, standpoint as recom-
mended in Briggs and O’Brien [29], quantifying uncertainty sur-
rounding the ICER and presenting results as cost-effectiveness
acceptability curves. If one wished to assume zero beneﬁt of
cinacalcet on the basis of the nonsigniﬁcant P value in the trial’s
primary (unadjusted ITT) analysis, the incremental cost of cina-
calcet therapy can be read directly from Table 3, that is, addi-
tional $46,875 over lifetime.The results of our economic model were most sensitive to the
treatment effect estimates, particularly the effects on survival:
treatment effect on mortality ranked as the highest inﬂuential
input parameter in the one-way sensitivity analysis. This is not
surprising for a lifetime economic analysis, and similar observa-
tions were made by others [30]. This effect was further evidenced
by the ICER of approximately $56,000 per QALY and the ICER of
approximately $116,000 per QALY associated with assumptions
of the lag-censoring effect estimates (20% improvement in mor-
tality) and the unadjusted ITT effect estimate (6% improvement
in mortality). The lag-censoring analysis assumes adherence to
cinacalcet and is therefore not fully representative of the real
world in which adherence to cinacalcet and other oral drugs is
known to decrease over time [31]. Excluding costs of commercial
cinacalcet from the conventional therapy arm increased the ICER
to approximately $90,000 per QALY, highlighting the sensitivity of
the model to the overall costs of cinacalcet, which was also seen
as one of the major sources of variance in the one-way sensitivity
analysis, whereas including stroke (an important outcome not
included in the primary composite end point of EVOLVE) did not
materially change the ICER.
Previous studies highlighted potential advantages of para-
thyroidectomies in terms of cost-effectiveness as compared with
pharmacotherapies [16,32]. The patient population in EVOLVE
was that with moderate-to-severe sHPT, and the median level of
PTH was 693 pg/ml. Surgery or medical therapy are both accept-
able methods of management of sHPT. Given the fact that most
patients on hemodialysis are considered to be at a relatively high
surgical risk, most patients are treated medically, and surgical
therapy is generally reserved for patients who are refractory to
medical therapy. Severe unremitting HPT occurred frequently in
the EVOLVE trial despite conventional therapy and cinacalcet
substantially reducing its occurrence [33]. Therefore, consistent
with the EVOLVE trial design, we modeled parathyroidectomies
as outcomes, rather than as treatment comparators. We then ex-
plored scenarios in which parathyroidectomies confer beneﬁcial
effects on the outcomes. Because randomized trials of
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conducted, and effects from observational research can be
biased, we made an assumption of 10% and 20% improvement
in the study outcomes postparathyroidectomy, which led to the
increase of the ICER to approximately $83,000 and $88,000
per QALY.
Another aspect of our work that sets it apart from other cost-
effectiveness analyses of cinacalcet, and many other medications
used in dialysis, is the accuracy and precision of the utility
estimates. The analysis of the EVOLVE EQ-5D data informs the
current economic model [43]. Thus, the utility inputs were
assessed for this speciﬁc population, for the speciﬁc events on
interest, including short-term and long-term effect, and also
estimating the direct effect of treatment. We did not explicitly
model adverse events because the related adverse events of
cinacalcet (principally nausea and vomiting) are considered
relatively minor and not costly. Their impact on patients is
implicitly included in the analysis of utilities. Because of the
positive, albeit small, overall beneﬁcial effect of cinacalcet on
health-related quality of life, we believe that symptom relief due
to cinacalcet [34] probably outweighs or at least balances any
potential short-term effects of adverse events.
The ﬁnal scenario included the cost of providing dialysis. This
approach reﬂects a limited societal perspective as discussed by
Russell et al. [35], that is, in which all costs and beneﬁts,
irrespective of who incurs them, should be included in the
analysis. All other assumptions are consistent with the recom-
mendations for societal perspective, including valuing all health
effects; using community-based utility weights; and discounting
costs and effects. We did not include costs due to productivity
loss because most of the patients undergoing dialysis are not
working or elderly [36]. Opportunity cost is often approximated by
the market price, although some argue that patent protection
laws distort markets and hence a discounted (40%–60%) price
would represent a more accurate opportunity cost [37]. To be
conservative, we used the market price (red book) as the measure
of opportunity costs. The limited societal perspective can serve as
a reference case to compare cost-effectiveness across programs,
but the practical utility of inclusion of dialysis costs in such an
analysis is debatable because cinacalcet is intended for the
treatment of sHPT and not for the underlying ESRD. Because
dialysis is an expensive procedure with annual Medicare expen-
diture on hemodialysis of $87,945 [25], the life-years gained
would incur additional lifetime costs because of prolongation of
dialysis treatment, and thus would likely bias the results against
any life-extending treatment of patients receiving dialysis. In
terms of making resource allocation decisions, this would mean
that patients requiring dialysis could be denied access to life-
extending therapies simply because dialysis is costly [38]. This
point of view is shared by others conducting cost-effectiveness
analyses in the dialysis population [11,30].
We conducted extensive probabilistic sensitivity analyses on
top of each scenario. Assuming that the efﬁcacy estimates from
covariate-adjusted ITT analysis represent in this case the least
biased and most relevant estimate, the results of the probabilistic
sensitivity analyses suggest a high probability (60%–80%) of cost-
effectiveness using the willingness-to-pay threshold of $100,000
per QALY [39]. The results for the unadjusted ITT analysis had
39% probability to be cost-effective, consistent with lower esti-
mated effects on outcomes.
An important limitation of our study is the heterogeneity of
the patient population in the EVOLVE trial as it is applied for the
economic assessment from the US perspective. Important
regional variations in age (i.e., younger patients in Latin America
and Russia than in the United States) increase generalizability,
but may slightly bias results as they pertain to patients in the
United States. We have addressed this by applying naturalisticevent rates from the US dialysis population to the conventional
therapy group leading to a very slight change in the ICER,
suggesting that the EVOLVE trial was not unduly biased by the
ex-US subpopulations, which is not surprising considering that
37% of the subjects were from the United States and 75% were
from Western countries with comparable demographic charac-
teristics. This mix of younger patients (who tend to have more
severe sHPT, thereby qualifying for enrollment), together with the
“healthy clinical trial participant effect,” may explain the differ-
ence in survival observed within the EVOLVE trial in comparison
to the general hemodialysis population. We used covariate-
adjusted treatment effects from the EVOLVE trial for the natural-
istic event rates scenario because the observed efﬁcacy should
apply directly to the general hemodialysis population as there
was no biologically plausible interaction of treatment effect by
covariates. There was some imprecision in estimating the costs
of concomitant medications for sHPT because we did not collect
information on the dose of phosphate binders. Cinacalcet, how-
ever, tends to lower serum phosphate concentrations relative to
conventional therapy (vitamin D sterols); therefore, a change in
the dose of phosphate binders was unlikely to yield a material
increase in costs in the cinacalcet group. We did not explicitly
model adverse reactions, which for cinacalcet may include, most
frequently, nausea, vomiting, and diarrhea [10]; because these
events are not costly and their impact on QALYs would be
expected to show in our utility analysis, we think that this
approach is reasonable. General limitations of Markov assump-
tions, that is, lack of memory, apply to our analysis, which we
have tried to address by keeping track of the event counts outside
of the Markov process. Despite limitations of the Markov
approach, we feel that its structure and process allowed a balance
between the ease of understanding and the complexity of sHPT
and its treatments.
In conclusion, the choice of treatment effect estimates used in
our model materially inﬂuenced the cost-effectiveness of cina-
calcet. In the unadjusted ITT analysis, cinacalcet does not
represent a cost-effective use of health care resources when
applying a willingness-to-pay threshold of $100,000 per QALY.
When using the covariate-adjusted ITT treatment effect, which
represents the least biased estimate, however, cinacalcet is a
cost-effective therapy for patients on hemodialysis with
moderate-to-severe sHPT.
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